Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment

被引:11
|
作者
Safer, Abdel-Majed [1 ]
Leporatti, Stefano [2 ]
机构
[1] Kuwait Univ, Fac Sci, Dept Biol Sci, Kuwait, Kuwait
[2] Ist Nanotecnol, CNR Nanotec, I-73100 Lecce, Italy
来源
关键词
chitosan; nanoparticles; drug delivery; antivirals; COVID-19; CHLOROQUINE; VACCINES; INHIBIT; VIRUS;
D O I
10.2147/IJN.S332385
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Chitosan has been investigated in several biological fields, including drug and gene delivery, tissue engineering antiviral and immunological adjuvant methods. It's a cationic copolymer of N-acetyl glucosamine and D-glucosamine with different molecular chain lengths, compositions, and sequences than N-acetyl glucosamine and D-glucosamine. It is biocompatible and cyto-compatible, as well as recyclable and bioresorbable. As effective drug delivery methods, chitosan nanoparticles are shaped into several pathways. The purpose of this article is to provide an overview of its antiviral application as a nanocarrier for antiviral medications, highlighting the benefits, limitations, and downsides. In this review, we will report the most recent COVID-19 vaccination advances. It will also be discussed what the future holds for chitosan nanoparticles in the treatment of coronaviruses.
引用
收藏
页码:8141 / 8158
页数:18
相关论文
共 50 条
  • [31] Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson's Disease
    Islam, Nazrul
    Rahman, Shafiqur
    CURRENT DRUG DELIVERY, 2022, 19 (03) : 260 - 265
  • [32] Drug delivery system based on PVA and clay for potential treatment of COVID-19
    Teodorescu, Mirela
    Morariu, Simona
    JOURNAL OF POLYMER RESEARCH, 2022, 29 (02)
  • [33] Drug delivery system based on PVA and clay for potential treatment of COVID-19
    Mirela Teodorescu
    Simona Morariu
    Journal of Polymer Research, 2022, 29
  • [34] Drug repurposing for the treatment of COVID-19
    Kato, Yuri
    Nishiyama, Kazuhiro
    Nishimura, Akiyuki
    Noda, Takamasa
    Okabe, Kaori
    Kusakabe, Takahiro
    Kanda, Yasunari
    Nishida, Motohiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2022, 149 (03) : 108 - 114
  • [35] COVID-19 Drug Treatment in China
    Fan L.
    Jiang S.
    Yang X.
    Wang Z.
    Yang C.
    Current Pharmacology Reports, 2020, 6 (4) : 146 - 154
  • [36] Drug treatment of COVID-19 infection
    Lui, Grace
    Guaraldi, Giovanni
    CURRENT OPINION IN PULMONARY MEDICINE, 2023, 29 (03) : 174 - 183
  • [37] Drug Repurposing in the Treatment of COVID-19
    Soylu, Mehmet
    Ozbek, Emine Nur
    Yetik Anacak, Gunay
    BEZMIALEM SCIENCE, 2020, 8 : 84 - 93
  • [38] Strategies to Promote Equity in COVID-19 Antiviral Treatment
    Fiscella, Kevin
    Sanders, Mechelle
    Yaeger, Jeffrey
    JAMA HEALTH FORUM, 2022, 3 (03):
  • [39] Investigational antiviral drugs for the treatment of COVID-19 patients
    Beheshtirouy, Samineh
    Khani, Elnaz
    Khiali, Sajad
    Entezari-Maleki, Taher
    ARCHIVES OF VIROLOGY, 2022, 167 (03) : 751 - 805
  • [40] Antiviral agents for the treatment of COVID-19: Progress and challenges
    Singh, Manmeet
    de Wit, Emmie
    CELL REPORTS MEDICINE, 2022, 3 (03)